Ignite Creation Date:
2025-12-24 @ 12:43 PM
Ignite Modification Date:
2025-12-28 @ 12:37 AM
Study NCT ID:
NCT06574061
Status:
COMPLETED
Last Update Posted:
2024-08-29
First Post:
2024-08-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of the Benefits of Sublingual AIT (PRACTIS)
Sponsor:
Stallergenes Greer
Organization:
Study Overview
Official Title:
Evaluation in Routine Practice of the Benefits of Sublingual Allergen Immunotherapy in Allergic Patients According to Different Modalities of Use
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRACTIS
Brief Summary:
The objective of the study was to evaluate in routine practice the benefits of sublingual allergen immunotherapy (SLIT) for allergic patients with allergic rhinitis (AR), with or without asthma, according to various methods of use (treatment regimen: formulation type, dose, duration, initiation) and type of allergen (grass pollen, tree pollen, herbaceous pollen, house dust mites, animal dander, moulds and poly-reactive types).
Detailed Description:
The treatment considered was any SLIT (tablet or liquid forms) accepted by the patient and the parent(s) in the case of minor patients. The treatment was taken as prescribed by the observing physician.
The expected benefits for patients after approximately 6 and 12 months after initiation of SLIT included:
* Decreased intensity of symptoms
* Decreased discomfort
* Decreased consumption of symptomatic treatments or associated treatments (especially in asthmatic patients)
* Improved quality of life
* Reduced absenteeism from school or work
* Beneficial impact on leisure activities.
The expected benefits for patients after approximately 6 and 12 months after initiation of SLIT included:
* Decreased intensity of symptoms
* Decreased discomfort
* Decreased consumption of symptomatic treatments or associated treatments (especially in asthmatic patients)
* Improved quality of life
* Reduced absenteeism from school or work
* Beneficial impact on leisure activities.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: